Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings

The FDA has put a clinical hold on Regenxbio’s RGX-121 over asymptomatic spine MRI findings, derailing the biotech’s plans to refile for approval of the once-rejected gene therapy candidate.